Home > Insider Trading > Filing (0001714899-25-000002)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1714899	Denali Therapeutics Inc.	DNLI	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1666236	E. Steve Krognes	C/O Denali Therapeutics Inc. 161 Oyster Point Blvd. South San Francisco CA 94080		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2024-12-31	30,000	$20.25	29,096	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	781,797	Indirect	See footnote

Footnotes

The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted December 1, 2023.
The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $20.10 to $20.55 per share. Upon request by the Commission staff, the Issuer, or asecurity holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
Reflects an allocation of 30,000 shares from the Steven Edward Krognes Revocable Trust to the Reporting Person.
Includes 13,467 Unvested RSUs.
The shares are held of record by The Steve Edward Krognes Revocable Trust U/A DTD 01/25/2016, for which the Reporting Person serves as trustee.